کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3804640 | 1245085 | 2015 | 4 صفحه PDF | دانلود رایگان |
Lower urinary tract symptoms (LUTS) affect more than 60% of men and women aged over 40. Symptoms may be classed as storage, voiding or post-micturition and have a variety of systemic, neurological, drug-related or urological causes. There is growing evidence that metabolic syndrome is linked to LUTS. Initial evaluation of LUTS should follow a structured system, with symptom scores and frequency/volume charts. Several features have been identified as risk factors for progression of LUTS and stratification using these factors can aid in planning management. For example, older age and a high-normal concentration of prostate-specific antigen may suggest a higher risk of progression to acute urinary retention. Many patients with LUTS will require no treatment. For those who do, the initial approach should be conservative, with lifestyle changes; this can be followed where necessary by drug treatment using selective α-adrenoceptor blockers, 5-α reductase inhibitors, antimuscarinics, mirabegron, or a combination of these. Phosphodiesterase-5 inhibitors can also improve symptom scores and quality of life, and may become part of the routine management of LUTS.
Journal: Medicine - Volume 43, Issue 8, August 2015, Pages 431–434